Ovarian cancer
Conditions
Interventions
Control group:Cytoreductive surgery + systemic chemotherapy
Trial group:Cytoreductive surgery + intraoperative HIPEC + systemic chemotherapy
Sponsors
Shanghai General Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years old; 2. Serous ovarian cancer, mucinous ovarian cancer, endometrioid ovarian cancer, fallopian tube cancer or primary peritoneal cancer; 3. Patients with newly diagnosed FIGO stage III (including neoadjuvant chemotherapy); 4. Patients with complete satisfactory reduction or residual lesions less than 1 cm; 5. Patients without other abdominal organ diseases and visceral metastasis; 6. Patients with ECoG score of 0 or 1; 7. Patients with normal blood routine, coagulation function and heart, liver and kidney function.
Exclusion criteria
Exclusion criteria: 1. Patients with evidence of pleural disease or lung metastasis; 2. Patients with peritoneal or mesenteric swelling or intestinal obstruction; 3. Patients with breast cancer or other abdominal and pelvic malignancies within 5 years before enrollment; 4. Patients with high risk factors of poor anastomotic healing, including anastomotic tissue ischemia and edema, obvious tension, severe hypoproteinemia, etc..
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| 2-year overall survival; | — |
Countries
China
Contacts
Public ContactXi Xiaowei
Shanghai First People's Hospital
Outcome results
None listed